Protagonist Therapeutics Inc (PTGX)

Apr 15, 2026

PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus

Apr 15, 2026

Apr 15, 2026

Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN

Apr 15, 2026

Apr 15, 2026

Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com

Apr 15, 2026

Apr 15, 2026

Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $121 - Moomoo

Apr 15, 2026

Apr 14, 2026

Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN

Apr 14, 2026

Apr 14, 2026

Jefferies reiterates Protagonist Therapeutics stock rating on Icotyde outlook By Investing.com - Investing.com Canada

Apr 14, 2026

Apr 14, 2026

Protagonist Therapeutics Jumps 7.0% in Broad Rally - AlphaStreet

Apr 14, 2026

Apr 14, 2026

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com South Africa

Apr 14, 2026

Apr 14, 2026

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com

Apr 14, 2026

Apr 11, 2026

Trading Systems Reacting to (PTGX) Volatility - Stock Traders Daily

Apr 11, 2026

Apr 10, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 10, 2026

Apr 09, 2026

PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill

Apr 09, 2026

Apr 08, 2026

Maintained Buy: Jefferies and Johnson Rice on Protagonist Therapeutics (PTGX) March 2026 - Meyka

Apr 08, 2026

Apr 08, 2026

PTGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Apr 08, 2026

AI Stocks: Is Protagonist Therapeutics Inc forming a bullish divergence2026 Chart Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Investor Mood: Will Protagonist Therapeutics Inc benefit from rate cuts2026 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn

Apr 07, 2026

Apr 07, 2026

Is Protagonist Therapeutics Inc stock good for income investors2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn

Apr 07, 2026

Apr 07, 2026

Protagonist Therapeutics Price Target Raised to $116.00/Share From $104.00 by Clear Street - Moomoo

Apr 07, 2026

Apr 07, 2026

PTGX: Clear Street Raises Price Target for Protagonist Therapeutics | PTGX Stock News - GuruFocus

Apr 07, 2026

Apr 06, 2026

Clear Street Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $116 - Moomoo

Apr 06, 2026

Apr 06, 2026

Clear Street raises Protagonist Therapeutics price target on drug potential By Investing.com - Investing.com India

Apr 06, 2026

Apr 06, 2026

Clear Street raises Protagonist Therapeutics price target on drug potential - Investing.com

Apr 06, 2026

Apr 06, 2026

SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Apr 06, 2026

Apr 06, 2026

Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN

Apr 06, 2026

Apr 05, 2026

Protagonist Therapeutics, Inc. (PTGX) stock price, news, quote and history - Yahoo Finance Singapore

Apr 05, 2026

Apr 05, 2026

Jobs Data: Will Protagonist Therapeutics Inc benefit from AI trends2026 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 04, 2026

Apr 04, 2026

Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge - Yahoo Finance

Apr 04, 2026

Apr 03, 2026

Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - Yahoo Finance UK

Apr 03, 2026

Apr 02, 2026

Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026

Apr 02, 2026

This Healthcare Stock Barely Flinches During Market Sell-Offs - The Motley Fool

Apr 02, 2026

Apr 02, 2026

PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 02, 2026

Apr 01, 2026

Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026 - Meyka

Apr 01, 2026

Apr 01, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Surges To New High Amid Nasdaq Today Focus - Kalkine Media

Apr 01, 2026

Apr 01, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year HighWhat's Next? - MarketBeat

Apr 01, 2026

Apr 01, 2026

Protagonist Therapeutics stock hits all-time high at 105.71 USD By Investing.com - Investing.com India

Apr 01, 2026

Mar 31, 2026

How Protagonist Therapeutics Inc. (PTGX) Affects Rotational Strategy Timing - Stock Traders Daily

Mar 31, 2026

Mar 31, 2026

Protagonist Therapeutics stock hits all-time high at 105.71 USD - Investing.com

Mar 31, 2026

Mar 30, 2026

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following ICOTYDE’s Phase 3 Psoriasis Data ReleaseLearn Why - simplywall.st

Mar 30, 2026

Mar 30, 2026

Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Protagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing - MarketScreener

Mar 30, 2026

Mar 28, 2026

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Reno Gazette Journal

Mar 28, 2026

Mar 28, 2026

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting - bitget.com

Mar 28, 2026

Mar 28, 2026

Protagonist presents one-year data for psoriasis drug ICOTYDE - Investing.com

Mar 28, 2026

Mar 28, 2026

Protagonist Therapeutics (MEX:PTGX) PE Ratio : At Loss (As of Mar. 28, 2026) - GuruFocus

Mar 28, 2026